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Abstract
Based on our previous analysis of HIV-1 isolates from Cameroon, we constructed a full-length infectious molecular clone from a primary
isolate belonging to the CRF02.AG group of recombinant viruses which dominate the HIV-epidemic in West and Central Africa. The virus
derived by transfection of the proviral clone pBD6-15 replicated with similar efficiency compared to its parental isolate and used CXCR4
as coreceptor as well. Furthermore, HIV-1 BD6-15 exhibited similar replication properties and virus yield as the reference B-type HIV-1
strain NL4-3. Sequence analysis revealed open reading frames for all structural and accessory genes apart from vpr. Phylogenetic and
bootscanning analyses confirmed that BD6-15 clusters with CRF02.AG recombinant strains from West and Central Africa with similar
cross-over points as described for the CRF02.AG prototype strain lbNG. Thus, pBD6-15 represents the first non-subtype B infectious
molecular clone of a fast replicating, high producer, X4-tropic primary HIV-1 isolate, which had only been briefly passaged in primary cells.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Sub-saharan Africa is the most affected region in the
human immunodeficiency virus type 1 (HIV-1) pandemic
harbouring about 70% of all persons infected with HIV. In
Central Africa, the presence of HIV-1 and HIV-2 of virtu-
ally all groups (HIV-1 group M, O, and N) and subtypes has
been reported (Takehisa et al., 1998; Heyndrickx et al.,
2000). To date, nine subtypes of HIV-1 group M have been
described with different subtypes dominating the epidemic
in different parts of the world. Furthermore, coinfection
with more than one subtype has led to the generation of
recombinants between different subtypes which have re-
placed their parental strains in some areas. Despite the
presence of many different subtypes in Central Africa, one
form of HIV-1 group M, the circulating recombinant form
(CRF), termed CRF02.AG, currently dominates the HIV
epidemic in this region. Genotypic studies showed that
approximately 60% of all viral isolates of West and Central
African origin are CRF02.AG viruses (Takehisa et al., 1998;
Heyndrickx et al., 2000; Montavon et al., 2000; Carr et al.,
2001). Subtype A and G viruses which are the putative
parental forms of CRF02.AG recombinants are also highly
prevalent in this region (Peeters et al., 2000). Several studies
have reported near full-length sequences of CRF02.AG vi-
ruses of West and Central African origin (Howard and
Rasheed, 1996; Montavon et al., 2000; Carr et al., 2001).
While providing important information regarding the mo-
lecular epidemiology of HIV-1, these sequence analyses do
not permit a detailed molecular characterisation of this virus
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group. Such studies require infectious molecular clones that
produce replication-competent virus following transfection
of permissive target cells.
Much of the currently available information on HIV-1
replication has been obtained from experiments with a few
infectious molecular clones. Besides their role in basic sci-
ence, such infectious clones are also important tools in
vaccine studies as well as for the development of antiviral
drugs and for the analysis of antiviral resistance. Most
replication-competent clones that exist to date represent
HIV-1 subtype B viruses, whose role in the epidemic is
limited to Europe and North America. Non-subtype B vi-
ruses from regions bearing the burden of HIV have not been
studied intensively until very recently. More than half of the
approximately 10 infectious molecular clones generated so
far are subtype B. More recently, infectious molecular
clones have also been generated for subtypes C, D, and the
CRF01.AE recombinant form (Gao et al., 1998; Salminen et
al., 2000; Ndung’u et al., 2001; Mukai et al., 2002). Two
recent reports described replication-competent molecular
clones from CRF02.AG recombinant viruses of Ghanaian
origin (Kusagawa et al., 2001; Takahoko et al., 2001). In
general, most non-B subtype derived infectious clones have
some limitations. For example, although having been gen-
erated from PBMCs, they may represent chimeras from two
different isolates (Ndung’u et al., 2001). Furthermore, com-
parison of the virus derived from the molecular clone with
its parental isolate or other reference strains is often lacking
(Gao et al., 1998). In the cases where these comparisons
were done, the replication kinetics and virus production was
significantly reduced for the virus derived from the infec-
tious clone, making these reagents difficult to work with
(Mukai et al., 2002). In the case of the CRF02.AG viruses,
the virus derived from the first replication-competent clone
was restricted in its host range, infecting T cell lines but not
peripheral blood mononuclear cells (PBMCs) (Kusagawa et
al., 2001). The virus derived from the other clone replicated
in PBMCs, albeit with slow replication kinetics compared to
other HIV isolates (Takahoko et al., 2001).
Previously we have characterised a panel of HIV-1 group
M primary isolates from Western Cameroon (Tebit et al.,
2002). To generate research tools for studying the dominant
viruses in Cameroon in particular and West and Central
Africa in general, we selected one of these isolates, termed
99CMBD6, based on its CRF02.AG genotype in gag, pol,
and env for full-length amplification and construction of the
infectious molecular clone pBD6-15. Virus derived from
transfection of this proviral clone replicated with similar
efficiency and kinetics compared to the parental virus iso-
late. Furthermore, HIV-1 BD6-15 exhibited similar replica-
tion properties and virus yield as the reference B-type
HIV-1 strain NL4-3 (Adachi et al., 1986). Thus, pBD6-15
represents the first non-subtype B infectious molecular
clone of a fast replicating, high producer, X4-tropic primary
HIV-1 isolate, which had only been briefly passaged in
primary cells.
Results and discussion
The blood sample 99CMBD6 originated from a 32-year-
old female Cameroonian suffering from AIDS. We have
previously reported a partial characterisation of the primary
isolate 99CMBD6, which was determined to be a member
of the CRF02.AG lineage (Tebit et al., 2002). We decided to
generate a full-length infectious molecular clone from this
isolate and compare its characteristics with that of the pa-
rental isolate and a reference strain. The redundancy of the
viral LTRs necessitated the amplification of the full-length
proviral genome of 99CMBD6 in two fragments. The 5
fragment extended from the 5 LTR to the reverse transcrip-
tase (RT) coding region in the pol gene, while the second
fragment extended from the RT coding region to the 3
LTR. Following long PCR and cloning of the respective 5
and 3 fragments, eight clones were obtained. Four of these
clones contained the 5 fragment (TOPO5frag1–4) and the
other four contained the 3 fragment (TOPO3frag1–4).
Subsequently, the 5 fragments were excised from the
TOPO5frag plasmids and inserted into the TOPO3frag
plasmids, thus generating a total of 16 full-length clones.
Virus production, virion protein composition, and infec-
tivity were tested for all 16 clones following transfection of
293T cells. Filtered supernatants from the transfections of
14 of the 16 full-length clones contained p24 antigen as
determined by antigen capture ELISA. These culture media
were therefore used to infect HIV-permissive C8166 cells.
Infectivity was determined by measuring p24 antigen and
monitoring for syncytia formation. Only 1 of the 14 trans-
fection supernatants was shown to contain infectious virus.
This infectious molecular clone was termed pBD6-15 and
was further characterised with respect to its protein compo-
sition, replication properties in different cell types, biolog-
ical phenotype, and coreceptor usage.
To determine the protein composition of the BD6-15
virus and of viruses obtained from some of the defective
molecular clones, we performed immunoblot analysis using
the serum of patient 99CMBD6 for detection. Viruses were
harvested from 293T cells transfected with the respective
full-length clone and were concentrated by ultracentrifuga-
tion through a sucrose cushion. Fig. 1 shows the compara-
tive analysis of particle fractions derived from pBD6-15,
three of the noninfectious full-length clones (pBD6-5,
pBD6-11, pBD6-13), the reference B-type clone pNL4-3,
and an HIV-1 group O clone. While transfection of
pBD6-11 did not lead to production of particulate HIV
antigen (Fig. 1, lane 4), transfection of pBD6-5 (lane 3) and
pBD6-13 (lane 5) yielded particles which exhibited a sim-
ilar protein profile as pBD6-15 (lane 6), but were produced
at lower efficiency. The patient serum detected the Gag-
derived proteins Pr55, matrix (MA), and capsid (CA) as
well as the Pol-derived protein integrase (IN) in all cases.
However, the ratio of Gag cleavage products to Pr55
polyprotein appeared to be significantly reduced in the two
defective viruses, indicating that there may be a processing
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defect. A very similar protein profile as for BD6-15 was
detected for the B-type isolate NL4-3. Less cross-reactivity
was observed for the O-type virus, whose MA and IN
proteins were not detected by the patient serum.
To determine the replication properties of the virus de-
rived from the infectious molecular clone pBD6-15, we
infected PBMCs and the T cell line C8166 with virus
produced by transfection of 293T cells and with the parental
isolate 99CMBD6. Virus derived from transfection of 293T
cells with pNL4-3 was used as a control. Fig. 2A shows that
the growth kinetics and virus production were very similar
for all three viruses in PBMCs. Furthermore, transfection-
derived BD6-15 virus also replicated with identical kinetics
in C8166 cells as its parental isolate, proving that this
molecular clone faithfully reproduced the properties of the
primary virus (Fig. 2B). Remarkably, BD6-15 exhibited
only a minor delay in replication kinetics in C8166 cells
when compared with the widely used and rapidly growing
B-type laboratory strain NL4-3.
The biological phenotype and coreceptor usage of trans-
fection-derived BD6-15 virus and the parental isolate were
determined on MT-2 and GHOST cells, respectively. Both
viruses exhibited identical properties: they induced syncytia
on MT-2 cells and exclusively used the coreceptor CXCR4
(data not shown). The two previously described CRF02.AG
molecular clones, on the other hand, were nonsyncytium
inducing and used CCR5 as coreceptor for entry (Takahoko
et al., 2001; Kusagawa et al., 2001), properties shared by
most infectious clones derived from primary isolates.
The described results showed that BD6-15 replicated
with very high efficiency in both T cell lines and PBMCs
and may therefore be used to produce high titer virus stocks
for biochemical and structural studies. We have recently
developed improved protocols for high-yield HIV-1 produc-
tion, which allowed preparation of milligram quantities of
infectious virus at high purity as judged by silver stain. To
compare virus production of BD6-15 and NL4-3 viruses,
MT-4 cells infected with the two viruses were expanded by
coculture and virus particles were purified by pelleting them
through a sucrose cushion and subsequent velocity gradient
centrifugation on an Iodixanol gradient. Virus preparations
from 200 ml of acutely infected MT-4 cells usually con-
tained 1–2 mg of virus at a titer of 108 tissue culture
infectious dose 50% (TCID50), and there was no major
difference between NL4-3 and BD6-15. Analysis of the
virion protein composition on silver-stained gels is shown in
Fig. 3. Two independent preparations of BD6-15 and a
preparation of NL4-3 revealed a very similar protein profile
with the Gag-derived proteins nucleocapsid (NC), MA, and
Fig. 1. Western blot analysis of virus derived from the infectious molecular
clones pBD6-15 (lane 6), from pNL4-3 (lane 1), from a HIV-1 group O
clone (lane 2), and from other clones derived from the isolate 99CMBD6
which were noninfectious (pBD6-5, pBD6-11, pBD6-13, respectively;
lanes 3, 4, and 5). 293T cells were transfected with the respective molec-
ular clones and culture supernatants obtained after 3 days were filtered and
centrifuged and virus pellets were separated by SDS–PAGE followed by
immunoblotting. Blots were reacted with serum from the AIDS patient
from whom virus 99CMBD6 had been isolated. HIV-specific proteins
matrix (MA), capsid (CA), integrase (IN), and the Gag polyprotein Pr55
are identified on the right.
Fig. 2. Replication kinetics of the virus derived from pBD6-15 in comparison with its parental isolate and the reference B-strain NL4-3. (A) Replication in
PBMCs; (B) replication in C8166 cells. Infection experiments were performed as described under Materials and methods and p24 antigen was monitored
every 2–3 days for 2 weeks (C8166) and 3 weeks (PBMCs), respectively. The data were obtained from a single experiment done in quadruplicate. Error bars
represent standard deviation.
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CA as well as the Gag polyprotein as major constituents,
confirming the high purity of these preparations. Thus,
pBD6-15 is the first infectious molecular clone from a
primary isolate that can be used for the large-scale produc-
tion of high-titered virus at high yield and purity. These
properties and the fact that it uses CXCR4 as a coreceptor
may permit its use as a reference tool in future studies.
We subsequently determined the complete sequence of
the HIV proviral genome in pBD6-15. Phylogenetic analy-
sis of the full-length sequence by the neighbour-joining
method showed that BD6-15 clusters with other reference
CRF02.AG viruses from West and Central Africa with a
high bootstrap value (Fig. 4; BD6-15 boxed). This was
further confirmed by using the similarity plot program in the
SIMPLOT package in which BD6-15 was compared to
reference isolates from eight different clades. BD6-15 ap-
peared to be most similar to the CRF02.AG prototype iso-
late IbNg throughout its genomic sequence (Fig. 5A). To
determine the putative cross-over points, the bootscanning
analysis program of the SIMPLOT package was used. A
total of nine cross-over points between subtypes A and G
was observed, indicating that BD6-15 is a complex A/G
recombinant virus. The cross-over points were in the fol-
lowing positions of the BD6-15 genome (Fig. 5B): nucleo-
tide 1600 (subtype A to subtype G), 2550 (G to A), 3450 (A
to G), 4050 (G to A), 5150 (A to G), 5650 (G to A), 7550
(A to G), 7950 (G to A), and 8450 (A to G). Phylogenetic
trees constructed with reference sequences of all subtypes
(data not shown) were used to support the various segments
shown in roman numerals in Fig. 5B. Nine of the 10 frag-
ments were confirmed to belong to either subtype A or G by
a significant bootstrap value 70% (data not shown). Frag-
ment (ix) which stretches from nucleotide 7951 to 8450 was
only tentatively classified as subtype A due to its low
bootstrap value of 52%.
The full-length sequence of BD6–15 is composed of
9774 nucleotides with the arrangement 5LTR, gag, pol, vif,
vpr, tat, vpu, rev, env, nef, and 3LTR. All reading frames
were open except for vpr, which had an in-frame stop codon
located 30 codons upstream of the normal vpr stop codon.
This in-frame stop codon was not detected in the parental
isolate upon direct pool sequencing of a PCR amplimer,
indicating that it may be due to a PCR-induced error or that
it represents a minor population in the primary isolate not
detectable by direct sequencing. Previous studies have also
shown the presence of in-frame stop codons in accessory
genes and especially in vpr in other proviral clones (Gao et
al., 1998). In the LTR, the putative binding sites for tran-
scriptional factors NF-B, SP1, and TATA were conserved.
A 16-nucleotide insertion downstream of the primer binding
site reported in some subtype A, G, and almost all known
CRF02.AG viruses was observed in BD6-15 as well. Anal-
ysis of the envelope region showed some minor deletions
and insertions, respectively, at the carboxyl-terminal ends of
the gp41 and gp120 sequences when compared to other
reference CRF02.AG sequences. The V3 loop sequence of
BD6-15 consisted of 37 amino acids and exhibited a single
amino acid difference compared to its parental isolate. The
crown of the V3 loop contained the GPGQAF motif which
is dominant among African HIV-1 isolates. In the amino
terminal region of nef, an insertion of 13 codons was ob-
served. Ten of these codons represented a duplication of the
sequence located only a few codons upstream. This inser-
tion, which is not subtype specific, has been found in many
isolates and was also observed in the recently described
CRF02.AG molecular clone (Kusagawa et al., 2001). It
varies from 6 to 13 amino acids in length in different
isolates.
In summary, pBD6-15 represents a full-length infectious
molecular clone derived from a typical X4-tropic primary
isolate of the CRF02.AG genotype, the virus which domi-
nates the HIV-epidemic in West and Central Africa. Several
properties make pBD6-15 a unique tool for the functional
characterisation of CRF02.AG viruses, for testing their re-
sponse to antiretroviral therapy and their probability for
resistance development, and for their application in vaccine
studies: (i) The virus used for construction of the full-length
clone had been isolated from PBMC and was passaged
exclusively in PBMC. (ii) The virus obtained by transfec-
tion of pBD6-15 exhibited identical replication properties
compared with its parental isolate, and (iii) replicated al-
most as efficiently as the laboratory-adapted B-type virus
NL4-3, the most widely used tool in molecular studies of
Fig. 3. Analysis of purified virus preparations on SDS gels stained with
silver. Virus derived from MT-4 cells infected with BD6-15 or NL4-3 was
purified by velocity gradient centrifugation and separated by SDS–PAGE,
and viral proteins were stained with silver nitrate. Lane 1 corresponds to
marker proteins (molecular mass in kDa shown to the left), lanes 2 and 3
correspond to two independent purifications of BD6-15, and lane 4 corre-
sponds to a purification of HIV-1 NL4-3. The positions of the Pr55gag
precursor and the structural proteins NC, MA, and CA are shown to the
right.
648 D.M. Tebit et al. / Virology 313 (2003) 645–652
HIV-1. (iv) The BD6-15 virus could be grown to high-
titered stocks (108 TCID50/ml) and (v) could be purified in
milligram quantities and to high purity. Thus, BD6-15 and
its infectious molecular clone pBD6-15 may serve as refer-
ence virus for the West and Central African epidemic.
Comparative molecular analysis of viruses and viral clones
representing different subtypes and recombinant forms will
be helpful to delineate the functional differences between
these viruses.
In a recent publication, Ellenberger et al. (2002) analysed
prevalent and incident HIV-1 strains in Coˆte d’Ivoire and
generated a consensus sequence for the CA and protease
regions. In this study, 90% of all sequences belonged to
the CRF02.AG group with a high sequence similarity com-
pared to the BD6-15 sequence. The ultimate goal of achiev-
ing sterilising immunity against all HIV strains appears
remote at best, and many current studies are attempting to
tailor regional vaccines that may be beneficial in certain
geographic areas without completely preventing infection.
Such studies require molecular tools representing the most
prevalent viral strains and the availability of a well-charac-
terised infectious molecular clone for the HIV group to
which more than 60% of viruses in West and Central Africa
belong will be important for future vaccine research. Fur-
thermore, following the current increase in the supply of
antiretroviral drugs, pBD6-15 may also be important for the
determination of drug susceptibility and resistance develop-
ment. It has been reported that subtype G viruses exhibit a
reduced sensitivity to protease inhibitors (Descamps et al.,
1998), and all CRF02.AG viruses are subtype G in the
protease region. Comparative studies are currently under
way to determine the relative susceptibility of BD6-15 to
clinically used protease inhibitors and to analyse whether
this virus shows an increased potential for resistance devel-
opment. Last, pBD6-15 may also be useful for the devel-
opment of recombinant virus assays to perform phenotypic
Fig. 4. Phylogenetic relationship of full-length genomic sequence of BD6-15 (boxed) with other HIV-1 strains. The tree was constructed using the
neighbour-joining method and reliability of the branching pattern was confirmed by bootstrapping (100 replicates). BD6-15 clusters with other members of
the CRF02.AG lineage mostly found in West and Central Africa. The HIV-1 subtypes and groups are represented on the right. Horizontal branch lengths are
drawn to scale, while vertical branch lengths are for clarity only. The scale bar at the bottom represents 10% divergence.
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analysis of resistance development on African HIV-1
strains.
Materials and methods
Construction of full-length proviral clones
Isolation of the HIV-1 primary isolate 99CMBD6 has
been described previously (Tebit et al., 2002). DNA was
extracted from PBMCs infected with 99CMBD6 and the
entire genome was amplified in two fragments using the
long-range polymerase chain reaction (Roche, Mannheim,
Germany). The 5 fragment ranged from the 5LTR to the
RT coding region while the 3 fragment stretched from
the RT coding region to the 3 LTR. The 5 fragment
was amplified with the primer pair MLUbase1
(GGGCCCACGCGTGATGGGTTAATTTACTCCAAGA-
AAAGACAAGA position 4–40 in HxB2) and Revsal2
(GAGTTCTCTGAAGTCGACTAATTTTCTCCA, posi-
tion 2760–2789 in HxB2), while the 3 fragment was am-
plified with the primer pair Forsal3 (TGGAGAAAATT-
AGTCGACTTCAGAGAACTCAATAAAAG, position
2760 –2797) and Notlast (AGTCGCGGCCGCGGTCT-
GAGGGATCTCTAGTTACCAGAGTC, position 9662–
9702). The Apa1, Mlu1, Sal1, and Not1 restriction sites
introduced in the primers to facilitate cloning are under-
lined. PCR products were cloned into the pCR-XL-TOPO
Fig. 5. (A) Similarity plot of the full-length genome sequence of BD6-15 compared with reference sequences of the subtypes indicated to the right. In this
analysis, a window size of 500 bases with an increment of 100 bases was used. BD6-15 is most similar to IbNG (thick grey line), the prototype strain of
CRF02.AG viruses. (B) Bootscan analysis of the BD6-15 sequence showing the crossover points relative to its putative parental subtypes A (black line) and
G (dark grey-dotted line). Sub-subtype F2 (light grey) was used as an out-group. The numbers at the bottom represent the positions on the HIV-1 genome
counting from the start codon of gag. The roman numerals indicate the gene fragments used to construct phylogenetic trees (not shown).
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TA vector (Invitrogen, Groningen, The Netherlands) and
correct clones were confirmed by restriction enzyme di-
gests. The 5 fragments were excised from the resulting
clones and inserted into the plasmids carrying the 3 frag-
ments using the newly introduced Apa1 and Sal1 restriction
sites. Cloning was done in a chessboard fashion as described
previously (Herchenro¨der et al., 1995).
Cells, transfections, and infections
293 T cells were maintained in Dulbecco’s minimal
Eagle’s medium supplemented with 10% inactivated fetal
calf serum, 100 U/ml penicillin, 100 g/ml streptomycin,
and 2 mM glutamin. Virus particles were produced by
transfecting 293 T cells with 15 g of plasmid DNA using
the calcium phosphate method. Culture supernatants were
harvested after 3 days, filtered through a 0.45-m filter, and
analysed by p24 antigen ELISA. Only p24 antigen ELISA-
positive cultures were used for further biological analysis.
HIV-1 permissive C8166 and MT-4 cells were main-
tained in RPMI 1640 with the supplements described above.
PBMCs were isolated from HIV-negative donors as de-
scribed (Tebit et al., 2002). Transfection-derived cell-free
virus supernatants were used to infect C8166 cells. Infec-
tivity was monitored by observing for syncytia formation
and p24 antigen determination. To generate virus stocks
from clones BD6-15, NL4-3, and the primary isolate
99CMBD6, C8166 cells were infected with transfection
derived virus for 5 days and the resulting supernatant was
used to determine the TCID50 by serial 10-fold dilutions of
virus on quadruplicate cultures of C8166.
Replication properties of BD6-15, its 99CMBD6 paren-
tal isolate, and NL4-3 were analysed comparatively in
C8166 cells and PBMCs. To this end, 5  105 C8166 cells
and 1.5  106 IL2/PHA-stimulated PBMCs were infected
with 500 TCID50 or 1500 TCID50 virus supernatant in
quadruplicate in a 48-well plate and incubated overnight at
37°C. The next day, the cells were washed twice with PBS,
resuspended in 1 ml RPMI 1640, and monitored for 2 and 3
weeks, respectively. Virus supernatants were taken every 2
to 3 days to measure p24 antigen production. The biological
phenotype and coreceptor usage of transfection-derived vi-
rus and of the primary isolate were determined, respec-
tively, on MT-2 cells and GHOST cells as described previ-
ously (Tebit et al., 2002).
Sequencing and sequence analysis
The entire genome of BD6-15 was sequenced by the
primer walking method using the dye terminator cycle se-
quencing kit on a CEQ 2000 capillary sequencer (Beck-
mann Coulter, CA, USA). Contigs were assembled using
the Contig Assembler of the Vector NTI Suite (Informax,
Oxford, UK). Sequences obtained were aligned with HIV-1
subtype reference sequences using the CLUSTAL  align-
ment program. Phylogenetic analysis was performed by the
neighbour-joining method. Statistical robustness of trees
and reliability of the branching pattern were confirmed by
bootstrapping. Similarity and bootscanning analysis to de-
termine recombination events were done with the SIM-
PLOT version 2.5 (Ray, 1999).
Purification of virus particles and analysis of viral
proteins
Culture medium from 293T cells transfected with the
respective molecular clones was filtered through a 0.45-m
pore-size filter and subsequently centrifuged through a
cushion of 20% (w/w) sucrose in PBS at 130,000 g for 90
min at 4°C. Virus pellets were resuspended in loading
buffer, subjected to sodium dodecyl sulfate (SDS)–polyac-
rylamide gel electrophoresis (PAGE), and proteins trans-
ferred to a nitrocellulose membrane (Schleicher & Schuell)
by electroblotting. Membranes were reacted with serum
from the AIDS patient from whom the virus 99CMBD6 was
isolated. Peroxidase-conjugated anti-human IgG antibody
(Jackson Immunochemicals) was used as the secondary
antibody and immune complexes were visualised by en-
hanced chemiluminescence (ECL System, Amersham) ac-
cording to the manufacturer’s instructions.
High-titer virus preparations of BD6-15 and NL4-3 were
produced essentially as described (Welker et al., 2000).
Briefly, MT-4 cells were initially infected with cell-free
virus and were subsequently expanded by cocultivation with
noninfected cells. Virus preparations were harvested before
a pronounced cytopathic effect was observed. Virus-con-
taining media were filtered and centrifuged through a su-
crose cushion as described above. Concentrated virus was
further purified by velocity gradient centrifugation on lo-
dixanol gradients as described (Dettenhofer and Yu, 1999)
and collected by ultracentrifugation. Gradient-purified virus
was resolved by SDS–PAGE and stained with silver as
described (Heukeshoven and Dernick, 1988).
Sequence data
The complete sequence of the BD6-15 infectious molec-
ular clone has been deposited in the GenBank under the
Accession No. AY271690.
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